NYSEARCA:TOVX - NYSE Arca - US87164U5083 - Common Stock - Currency: USD
NYSEARCA:TOVX (2/21/2025, 8:04:00 PM)
1.55
-0.06 (-3.73%)
The current stock price of TOVX is 1.55 USD. In the past month the price increased by 13.14%. In the past year, price decreased by -86.67%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Theriva Biologics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland and currently employs 21 full-time employees. Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The company is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.
THERIVA BIOLOGICS INC
9605 Medical Center Drive, Suite 270
Rockville MARYLAND US
Employees: 22
Company Website: https://therivabio.com/
Investor Relations: https://therivabio.com/investors/
Phone: 17343327800
The current stock price of TOVX is 1.55 USD. The price decreased by -3.73% in the last trading session.
The exchange symbol of THERIVA BIOLOGICS INC is TOVX and it is listed on the NYSE Arca exchange.
TOVX stock is listed on the NYSE Arca exchange.
8 analysts have analysed TOVX and the average price target is 6.12 USD. This implies a price increase of 294.84% is expected in the next year compared to the current price of 1.55. Check the THERIVA BIOLOGICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
THERIVA BIOLOGICS INC (TOVX) has a market capitalization of 4.31M USD. This makes TOVX a Nano Cap stock.
THERIVA BIOLOGICS INC (TOVX) currently has 22 employees.
THERIVA BIOLOGICS INC (TOVX) has a support level at 1.33 and a resistance level at 1.6. Check the full technical report for a detailed analysis of TOVX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TOVX does not pay a dividend.
THERIVA BIOLOGICS INC (TOVX) will report earnings on 2025-03-24, after the market close.
THERIVA BIOLOGICS INC (TOVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-29.25).
The outstanding short interest for THERIVA BIOLOGICS INC (TOVX) is 10.32% of its float. Check the ownership tab for more information on the TOVX short interest.
ChartMill assigns a technical rating of 4 / 10 to TOVX. When comparing the yearly performance of all stocks, TOVX is a bad performer in the overall market: 91.41% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to TOVX. TOVX has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months TOVX reported a non-GAAP Earnings per Share(EPS) of -29.25. The EPS increased by 7.87% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -66.55% | ||
ROE | -108.35% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to TOVX. The Buy consensus is the average rating of analysts ratings from 8 analysts.